Safety of biologic therapies during pregnancy in women with rheumatic disease

Table 3 Others biological agents use during pregnancy and the conception period

Ref./study	No. of pregnancies	Disease	Biologic drugs	Pregnancy stage	Pregnancy outcome
Berger et al[56] Fischer-Betz et al[57] Case report	3	AOSD	ANK	Through pregnancy	3 healthy live birth, full-term deliveries
Rubbert-Roth et al[58] Case series from clinical trials	33	RA	TCZ	Non-data	26/32 treated wit TCZ + MTX, 6/32 TCZ monotherapy or concomitant with DMARD other than MTX 10/33 healthy live birth at term; 1/33 (1 infant died of ARDS 3 d after emergency cesarean section for intrapartum fetomaternal hemorrhage due to placenta previa; 13/33 elective terminations, 7/33 miscarriages
Chakravarty et al[59]	153	NHL, RA, SLE, Others1	RTX	132 prior to the conception	90 live births: 68 full-term deliveries; 22 preterm; 1 neonatal death at 6 wk; 2 malformations (clubfoot in one twin, and cardiac malformation in a singleton birth)
Biogen Idec/Genentech/Roche rituximab global drug safety database				21 after the concption	11 newborns had hematologic abnormalities (none with infections); 4 neonatal infections (fever, bronchiolitis, cytomegalovirus hepatitis, and chorioamnionitis)
Ojeda-Uribe et al[22]	1	RA	ABT	First trimester	No complications. One healthy live birth

¹Idiopathic purpura thrombocytopenic, autoimmune haemolytic anaemia, multiple sclerosis, thrombotic thrombocytopenia. Purpura, Castleman disease, mixed connective tissue disease, and renal transplantation. AOSD: Adult onset still disease; RA: Rheumatoid arthritis; NHL: No hodgkin lymphoma; SLE: Systemic lupus erythematosus; ANK: Anakinra; TCZ: Tocilizumab; RTX: Rituximab; ABT: Abatacept; ARDS: Acute respiratory distress syndrome.